Business Context and Reporting Period
This Form 8-K was filed by ImmunityBio, Inc. (IBRX) on December 5, 2022, reporting events occurring on December 2, 2022. The filing addresses the resolution of a long-standing arbitration dispute involving the Company, its wholly-owned subsidiary NantCell, Inc., and a joint venture partner, Sorrento Therapeutics, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The primary financial data point disclosed is the outcome of the arbitration award:
- Total Arbitration Award: $173.5 million
- Amount Payable to ImmunityBio: $156.8 million
- Amount Payable to NANTibody (Joint Venture): $16.7 million (remainder of total)
Material Changes
The material change reported is the finalization of an arbitration proceeding initiated in 2019 regarding fraud, breach of contract, and unjust enrichment claims against Sorrento Therapeutics, Inc. and its CEO, Dr. Henry Ji. The arbitrator ruled in favor of the Claimants, determining that Sorrento breached two exclusive license agreements. Additionally, the arbitrator issued declaratory relief confirming that the license agreements remain in full force and effect specifically regarding ImmunityBio's PD-L1 NK cell, while terminating rights and obligations for other targets.
Outlook, Risks, and Management Commentary
Management intends to promptly pursue confirmation of the award to obtain a judgment and will vigorously pursue the collection of the $156.8 million award plus applicable interest from Sorrento. However, the Company explicitly states it makes no assurances regarding the receipt of the full amount or the timing of such receipt. The filing notes that other previously disclosed disputes between the Company and Sorrento remain unresolved by this decision.
Investor Verification Checklist
- Verify the current financial status and solvency of Sorrento Therapeutics, Inc. to assess the collectability of the $156.8 million award.
- Monitor legal filings for the confirmation of the arbitration award and any subsequent appeals or enforcement actions.
- Review the status of other unresolved disputes between ImmunityBio and Sorrento mentioned in the filing.
- Confirm the operational impact of the declaratory relief regarding the PD-L1 NK cell license on future product development.